Comparing PRIME and EU Pathways: Long -Term Strategy and Global Impact
In the European Union (EU), the European Medicines Agency (EMA) has implemented several expedited regulatory pathways, notably the PRIority MEdicines (PRIME) scheme, to facilitate the development and approval of promising medicines. Launched in March 2016, the PRIME scheme aims to enhance support for the development of medicines that target an unmet medical need. In addition […]
Comparing PRIME and EU Pathways: Long -Term Strategy and Global Impact Read More »